Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 10/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | POLQ | O75417 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232803 | 0.87 | MAPK10 (0.49) | MAPK3MAPK1MAPK9MAPK10PTK2 | |
| SCHEMBL12900283 | 0.86 | MAPK10 (0.66) | MAPK3MAPK1MAPK9MAPK10PTK2 | |
| SCHEMBL12901104 | 0.82 | MAPK3 (0.53) | MAPK3MAPK1MAPK9MAPK10PTK2 | |
| SCHEMBL12900862 | 0.81 | MAPK3 (0.58) | MAPK3MAPK1MAPK9MAPK10PTK2 | |
| SCHEMBL12900858 | 0.79 | MAPK10 (0.48) | MAPK3MAPK1MAPK9MAPK10PTK2 | |
| SCHEMBL1232347 | 0.78 | NUDT1 (0.58) | MAPK3MAPK1MAPK9MAPK10PTK2 | |
| SCHEMBL1231919 | 0.75 | MAPK9 (0.56) | MAPK3MAPK1MAPK9MAPK10PTK2 | |
| SCHEMBL20320529 | 0.75 | MAPT (0.45) | MAPK3MAPK1MAPK9MAPK10PTK2 | |
| SCHEMBL1417632 | 0.75 | POLB (0.46) | PTK2NUDT1ULK1LMNAPOLB | |
| SCHEMBL1231920 | 0.73 | MAPK10 (0.72) | MAPK3MAPK1MAPK9MAPK10PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | PTK2, CABLES1, TNK2 | MAPK3 185/4885MAPK1 205/4885MAPK9 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.